Offstream
news

---

Changes

1. The FDA announces that it has approved the Novavax COVID-19 vaccine for United States teens between the ages of 12 and 17.
   2022-08-21 06:03:43 (First version)
2. The FDA announces that it has approved the Novavax COVID-19 vaccine for youths between the ages of 12 and 17.
   (Current version)

---

Related

The U.S. FDA grants approval for the Pfizer–BioNTech COVID-19 vaccine for people aged between 12 and 17.
2022-07-8

The Australian Technical Advisory Group on Immunisation recommends the usage of the Novavax COVID-19 vaccine as a booster dose.
2022-03-2

The Singaporean Health Sciences Authority grants interim authorisation for the use of the protein-based Novavax COVID-19 vaccine.
2022-02-14

The Food and Drug Administration authorizes the use of the Pfizer–BioNTech COVID-19 vaccine as a booster dose for children between the ages of 12 and 15 years, becoming the world's first vaccine to be authorized as a booster shot for this age group.
2022-01-3

The U.S. Food and Drug Administration says that it has granted priority review for the vaccine developed by Pfizer and BioNTech. A decision on whether to fully approve the vaccine will likely be made within two months.
2021-07-16

Phase III clinical trials for the Novavax COVID-19 vaccine candidate conclude in the U.S. and Mexico, showing an efficacy rating of 90.4%, down from the initial estimate of 96.4% efficacy reported in March. Additionally, the vaccine candidate was also found to be 86.3% effective against the Lineage B.1.1.7 Alpha variant that originated in the United Kingdom.
2021-06-14

Johnson & Johnson's single-shot COVID-19 vaccine candidate meets the standards for emergency use authorization, according to analysis from a committee within the FDA, though formal authorization will not be determined until February 26. The vaccine is 66% effective in combating the virus and can be stored in normal refrigerators.
2021-02-24

The U.S. Food and Drug Administration authorizes the Moderna COVID-19 vaccine for emergency use.
2020-12-18

Pfizer and BioNTech apply for an emergency use authorization from the U.S. Food and Drug Administration for their vaccine. If the application is approved, the vaccine will likely be limited and rolled out in phases.
2020-11-20

President Donald Trump and the Food and Drug Administration (FDA) announce the emergency use authorization of convalescent plasma for COVID-19 patients after days of White House officials suggesting there were politically motivated delays by the FDA in approving a vaccine and therapeutics for the disease that President Trump claims has harmed his re-election chances. The FDA said more than 70,000 patients have been treated with convalescent plasma, but they have not yet obtained enough randomized clinical trial data on convalescent plasma for COVID-19. Some of those trials are underway.
2020-08-23